SK12402002A3 - Kompozícia pre prevenciu a/alebo liečenie cievnych ochorení obsahujúca propionyl L-karnitín a koenzým Q10 - Google Patents

Kompozícia pre prevenciu a/alebo liečenie cievnych ochorení obsahujúca propionyl L-karnitín a koenzým Q10 Download PDF

Info

Publication number: SK12402002A3
Authority: SK; Slovakia
Prior art keywords: carnitine; coenzyme; propionyl; composition; acid
Prior art date: 2000-03-02

Application number

SK1240-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Claudio Cavazza

Original Assignee

Sigma-Tau Healthscience S. P. A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-02

Filing date

2001-02-20

Publication date

2003-02-04

2001-02-20 Application filed by Sigma-Tau Healthscience S. P. A. filed Critical Sigma-Tau Healthscience S. P. A.

2003-02-04 Publication of SK12402002A3 publication Critical patent/SK12402002A3/sk

Links

UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title claims abstract description 63
239000000203 mixture Substances 0.000 title claims abstract description 33
238000011282 treatment Methods 0.000 title claims abstract description 12
230000002265 prevention Effects 0.000 title claims abstract description 10
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title abstract description 48
235000017471 coenzyme Q10 Nutrition 0.000 title abstract description 11
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title abstract description 5
229940110767 coenzyme Q10 Drugs 0.000 title abstract description 5
208000019553 vascular disease Diseases 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
230000032683 aging Effects 0.000 claims abstract description 7
235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
230000002093 peripheral effect Effects 0.000 claims abstract description 6
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 50
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 30
239000005515 coenzyme Substances 0.000 claims description 28
239000002253 acid Substances 0.000 claims description 14
229960004203 carnitine Drugs 0.000 claims description 14
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 9
230000002792 vascular Effects 0.000 claims description 9
238000000034 method Methods 0.000 claims description 7
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
-1 fumaran Substances 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
208000014644 Brain disease Diseases 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000011976 maleic acid Substances 0.000 claims description 3
239000006187 pill Substances 0.000 claims description 3
239000006188 syrup Substances 0.000 claims description 3
235000020357 syrup Nutrition 0.000 claims description 3
239000003826 tablet Substances 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
229940024606 amino acid Drugs 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
239000007937 lozenge Substances 0.000 claims 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
208000035475 disorder Diseases 0.000 abstract description 5
230000000747 cardiac effect Effects 0.000 abstract description 3
208000020358 Learning disease Diseases 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract description 2
230000002490 cerebral effect Effects 0.000 abstract description 2
201000003723 learning disability Diseases 0.000 abstract description 2
230000010485 coping Effects 0.000 abstract 1
238000012360 testing method Methods 0.000 description 22
241001465754 Metazoa Species 0.000 description 16
230000000694 effects Effects 0.000 description 12
230000002195 synergetic effect Effects 0.000 description 12
206010021143 Hypoxia Diseases 0.000 description 9
QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 8
208000007536 Thrombosis Diseases 0.000 description 7
230000001681 protective effect Effects 0.000 description 7
230000002503 metabolic effect Effects 0.000 description 6
210000003657 middle cerebral artery Anatomy 0.000 description 6
210000003540 papillary muscle Anatomy 0.000 description 6
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000007954 hypoxia Effects 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
206010002660 Anoxia Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
230000002407 ATP formation Effects 0.000 description 2
241000976983 Anoxia Species 0.000 description 2
102000002045 Endothelin Human genes 0.000 description 2
108050009340 Endothelin Proteins 0.000 description 2
102100033902 Endothelin-1 Human genes 0.000 description 2
101800004490 Endothelin-1 Proteins 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 2
RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 2
229930003316 Vitamin D Natural products 0.000 description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000007953 anoxia Effects 0.000 description 2
230000000879 anti-atherosclerotic effect Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
229960002646 scopolamine Drugs 0.000 description 2
229960002718 selenomethionine Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
235000019160 vitamin B3 Nutrition 0.000 description 2
239000011708 vitamin B3 Substances 0.000 description 2
235000019166 vitamin D Nutrition 0.000 description 2
239000011710 vitamin D Substances 0.000 description 2
150000003710 vitamin D derivatives Chemical class 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
229940046008 vitamin d Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229940071566 zinc glycinate Drugs 0.000 description 2
UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 2
RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
XKMMPOZUNZUYMJ-WHASPQHYSA-N C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O.O[C@@H](C[N+](C)(C)C)CC([O-])=O Chemical compound C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O.O[C@@H](C[N+](C)(C)C)CC([O-])=O XKMMPOZUNZUYMJ-WHASPQHYSA-N 0.000 description 1
BECDNPYMOGYIDI-AYEYZUDDSA-N C(CC)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O.C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O Chemical compound C(CC)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O.C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O BECDNPYMOGYIDI-AYEYZUDDSA-N 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 1
102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical group COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000001147 anti-toxic effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
229940019899 coenzyme Q10 50 mg Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000008279 sol Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000012549 training Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

SK1240-2002A 2000-03-02 2001-02-20 Kompozícia pre prevenciu a/alebo liečenie cievnych ochorení obsahujúca propionyl L-karnitín a koenzým Q10 SK12402002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2000RM000106A IT1316997B1 (it)	2000-03-02	2000-03-02	Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10.
PCT/IT2001/000081 WO2001064203A2 (en)	2000-03-02	2001-02-20	Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10?

Publications (1)

Publication Number	Publication Date
SK12402002A3 true SK12402002A3 (sk)	2003-02-04

Family

ID=11454491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1240-2002A SK12402002A3 (sk)	2000-03-02	2001-02-20	Kompozícia pre prevenciu a/alebo liečenie cievnych ochorení obsahujúca propionyl L-karnitín a koenzým Q10

Country Status (19)

Country	Link
US (1)	US6814972B2 (pl)
EP (1)	EP1263423B1 (pl)
AR (1)	AR027958A1 (pl)
AT (1)	ATE335473T1 (pl)
AU (2)	AU2001241030B8 (pl)
CA (1)	CA2400959C (pl)
CY (1)	CY1106168T1 (pl)
CZ (1)	CZ20022758A3 (pl)
DE (1)	DE60122114T2 (pl)
DK (1)	DK1263423T3 (pl)
ES (1)	ES2269355T3 (pl)
HU (1)	HU229421B1 (pl)
IT (1)	IT1316997B1 (pl)
MX (1)	MXPA02008532A (pl)
PL (1)	PL207536B1 (pl)
PT (1)	PT1263423E (pl)
SK (1)	SK12402002A3 (pl)
TN (1)	TNSN01033A1 (pl)
WO (1)	WO2001064203A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002309038B2 (en) *	2001-05-10	2007-05-17	Kaneka Corporation	Compositions for transmucosal administration containing coenzyme Q as the active ingredient
TW200304373A (en) *	2002-03-20	2003-10-01	Kanegafuchi Chemical Ind	Percutaneous absorption promoters and compositions for treating athlete's foot
US8377454B2 (en)	2009-05-01	2013-02-19	Parviz Gharagozloo	Treating male infertility secondary to sperm oxidative stress
PT2582368T (pt) *	2010-06-16	2018-06-04	Alfasigma Spa	Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1291113B1 (it) *	1997-03-20	1998-12-29	Sigma Tau Ind Farmaceuti	Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CA2284738C (en) *	1997-03-27	2008-12-23	Michael J. Sole	Nutritional composition for improvements in cell energetics
US6232346B1 (en) *	1997-03-27	2001-05-15	Michael J. Sole	Composition for improvement of cellular nutrition and mitochondrial energetics
IT1299197B1 (it) *	1998-06-30	2000-02-29	Sigma Tau Healthscience Spa	Composizione ad attivita' antiossidante, antiproliferativa, energetica e atta a migliorare l'utilizzazione metabolica del glucosio.
IT1306130B1 (it) *	1999-04-16	2001-05-30	Sigma Tau Healthscience Spa	Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
IT1306133B1 (it)	1999-04-22	2001-05-30	Sigma Tau Healthscience Spa	Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
IT1317008B1 (it)	2000-04-04	2003-05-26	Sigma Tau Healthscience Spa	Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare.

2000
- 2000-03-02 IT IT2000RM000106A patent/IT1316997B1/it active
2001
- 2001-02-20 EP EP01912113A patent/EP1263423B1/en not_active Expired - Lifetime
- 2001-02-20 CA CA2400959A patent/CA2400959C/en not_active Expired - Lifetime
- 2001-02-20 AU AU2001241030A patent/AU2001241030B8/en not_active Expired
- 2001-02-20 PT PT01912113T patent/PT1263423E/pt unknown
- 2001-02-20 SK SK1240-2002A patent/SK12402002A3/sk unknown
- 2001-02-20 AU AU4103001A patent/AU4103001A/xx active Pending
- 2001-02-20 MX MXPA02008532A patent/MXPA02008532A/es active IP Right Grant
- 2001-02-20 DE DE60122114T patent/DE60122114T2/de not_active Expired - Lifetime
- 2001-02-20 AT AT01912113T patent/ATE335473T1/de active
- 2001-02-20 WO PCT/IT2001/000081 patent/WO2001064203A2/en not_active Ceased
- 2001-02-20 ES ES01912113T patent/ES2269355T3/es not_active Expired - Lifetime
- 2001-02-20 DK DK01912113T patent/DK1263423T3/da active
- 2001-02-20 PL PL358178A patent/PL207536B1/pl unknown
- 2001-02-20 CZ CZ20022758A patent/CZ20022758A3/cs unknown
- 2001-02-20 US US10/220,186 patent/US6814972B2/en not_active Expired - Lifetime
- 2001-02-20 HU HU0204467A patent/HU229421B1/hu not_active IP Right Cessation
- 2001-02-26 AR ARP010100861A patent/AR027958A1/es unknown
- 2001-02-27 TN TNTNSN01033A patent/TNSN01033A1/fr unknown
2006
- 2006-09-25 CY CY20061101373T patent/CY1106168T1/el unknown

Also Published As

Publication number	Publication date
MXPA02008532A (es)	2003-02-12
CY1106168T1 (el)	2011-06-08
ITRM20000106A0 (it)	2000-03-02
AR027958A1 (es)	2003-04-16
DE60122114D1 (de)	2006-09-21
ES2269355T3 (es)	2007-04-01
DE60122114T2 (de)	2007-02-08
ITRM20000106A1 (it)	2001-09-02
DK1263423T3 (da)	2006-12-11
AU2001241030B8 (en)	2005-10-20
WO2001064203A3 (en)	2002-03-28
ATE335473T1 (de)	2006-09-15
AU4103001A (en)	2001-09-12
EP1263423B1 (en)	2006-08-09
PT1263423E (pt)	2006-11-30
CA2400959C (en)	2011-01-04
US6814972B2 (en)	2004-11-09
US20030059418A1 (en)	2003-03-27
PL358178A1 (pl)	2004-08-09
HUP0204467A2 (hu)	2003-06-28
PL207536B1 (pl)	2010-12-31
HUP0204467A3 (en)	2006-07-28
EP1263423A2 (en)	2002-12-11
AU2001241030B2 (en)	2005-09-15
CA2400959A1 (en)	2001-09-07
WO2001064203A2 (en)	2001-09-07
HU229421B1 (en)	2013-12-30
TNSN01033A1 (fr)	2005-11-10
IT1316997B1 (it)	2003-05-26
CZ20022758A3 (cs)	2003-02-12

Publication	Publication Date	Title
US8518455B2 (en)	2013-08-27	Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
US6245378B1 (en)	2001-06-12	Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals
US5780489A (en)	1998-07-14	Method for treating amyotrophic lateral sclerosis
US6515020B1 (en)	2003-02-04	Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
Maddrey	1985	Branched chain amino acid therapy in liver disease.
CA2400959C (en)	2011-01-04	Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10
AU2001241030A1 (en)	2001-11-22	Composition for the prevention and/or treatment of vascular diseases, comprising propionyl L-carnitine and coenzyme Q10
US20020002202A1 (en)	2002-01-03	Use of fumarate salt of L-carnitine or its alkanoyl derivatives in ischaemia
CZ20022759A3 (cs)	2003-02-12	Přípravek k prevenci a/nebo léčbě cytotoxických účinků vyvolaných používáním imunosupresivních látek
MXPA01003569A (es)	2002-05-09	Combinacion de carnitinas y resveratrol para prevenir o tratar enfermedades cerebrales y del envejecimiento